Inovio Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
529900B9W875XDZXTM97 - ISIN
US45773H4092 (INO )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Read full profile
Fundamentals
- Net revenue
€709.66K - Gross margin
100.0% - EBIT
-€122.77M - EBIT margin
-17,300.3% - Net income
-€115.25M - Net margin
-16,239.9%
Statement period: - (published )
Stock price
Dividends
- Last dividend amount
-
$0.01 - Ex date
-
- Payment date
-
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: May 13, 2024 (Q1 2024)